Compare NBP & QADR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBP | QADR |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.5M | 249.3M |
| IPO Year | 2019 | 2025 |
| Metric | NBP | QADR |
|---|---|---|
| Price | $1.97 | $9.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 233.2K | 25.5K |
| Earning Date | 04-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $9.91 |
| 52 Week High | $5.19 | $9.99 |
| Indicator | NBP | QADR |
|---|---|---|
| Relative Strength Index (RSI) | 64.83 | 59.44 |
| Support Level | $1.67 | $9.92 |
| Resistance Level | $2.27 | $9.98 |
| Average True Range (ATR) | 0.08 | 0.01 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 96.15 | 75.00 |
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
QDRO Acquisition Corp is a blank check company.